Inhibitor – Page 10

Alecensa: FDA-Approved First ALK Inhibitor for Adjuvant Treatment in Early-Stage ALK-Positive NSCLC

2 years ago talkbio0Tagged Alecensa, ALINA, ALK gene, ALK Positive, Approved, Cessation of life, disease recurrence, Early-stage, genentech, Guidelines, Immunologic Adjuvants, Inhibitor, NCCN, Non-Small Cell Lung Carcinoma, Roche (company), United States Food and Drug Administration

Alecensa, ALK Inhibitor, Adjuvant Treatment, Early-Stage ALK-Positive NSCLC, FDA Approval, Genentech, Roche Group, ALINA Study, 76% Reduction in Disease Recurrence or Death, NCCN Guidelines

AstraZeneca’s Lynparza Demonstrates Nearly 50% Response in Advanced Breast Cancer Patients: #AACR24 Update

2 years ago talkbio0Tagged 50, AACR24, advanced breast cancer, AstraZeneca, Frequency of Responses, Inhibitor, Lynparza, olaparib, PARP1 gene

AstraZeneca, Lynparza (olaparib), PARP inhibitor, Advanced breast cancer, 50% response rate, AACR24

Jazz Pharmaceuticals Expands Oncology Pipeline with Redx’s KRAS Inhibitor Program

2 years ago talkbio0Tagged Inhibitor, Jazz, Kirsten murine sarcoma virus, Redx

Kirsten murine sarcoma virus, Jazz, Redx, Inhibitor